Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Metrics to compare | ACW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACWPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.2x | −3.3x | −0.6x | |
PEG Ratio | 13.47 | −0.04 | 0.00 | |
Price/Book | 4.8x | 2.2x | 2.6x | |
Price / LTM Sales | 9.5x | 10.0x | 3.2x | |
Upside (Analyst Target) | - | 218.2% | 46.2% | |
Fair Value Upside | Unlock | 11.9% | 7.0% | Unlock |